TIGIT and glioblastoma: [24, 25, 26] Notably, a recent clinical case demonstrated remarkable efficacy using neoadjuvant triple‐ICI therapy prior to surgery, achieving 17 months of relapse‐free survival in advanced GBM.[27] Emerging immunotherapeutic targets, such as poliovirus receptor cell adhesion molecule (CD155), T cell immunoreceptor with Ig and ITIM domains (TIGIT), CD226, cytotoxic T‐lymphocyte associated protein 4, lymphocyte activating 3, and MHC‐related pathways,[28, 29, 30, 31, 32] hold great promise for GBM treatment.